First AD

Second AD

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma.

Locoregional Therapies for Intermediate-Stage HCC

Hepatocellular Carcinoma

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma

UCLA Health Jonsson Comprehensive Cancer Center

Cancer Centers

Partner

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma, including transarterial chemoembolization (TACE) and radioembolization.

Examining the Role of Liver Function in HCC

HCC Staging: Improving Treatment Strategies

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Emerging Therapies in Intermediate-Stage HCC 

Updates from IMbrave150, LEAP-002, and HIMALAYA Trials 

Comorbidity Considerations for HCC Treatment

The Evolving Landscape of Second-Line Therapies in HCC Management

Additional Second-Line Treatments for HCC

Real-World Evidence on Second-Line Therapy Selection and Outcomes 

Pioneering Breakthroughs in HCC Treatment